PDCD5抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07530(PDCD5 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

PDCD5 (Programmed Cell Death 5), also known as TFAR19. is a pro-apoptotic protein that plays critical roles in regulating cell cycle progression, apoptosis, and DNA damage repair. It interacts with key apoptotic regulators, such as p53. and enhances apoptosis by stabilizing p53 and promoting its translocation to the nucleus. PDCD5 is ubiquitously expressed in normal tissues, but its expression is frequently downregulated or lost in various cancers, including leukemia, breast cancer, and hepatocellular carcinoma, suggesting its potential role as a tumor suppressor.

PDCD5 antibodies are immunological tools developed to detect and quantify PDCD5 protein levels in research and diagnostic applications. These antibodies, including monoclonal and polyclonal variants, are essential for studying PDCD5's biological functions, its interaction networks, and its dysregulation in diseases. In cancer research, PDCD5 antibodies help assess PDCD5 expression patterns, correlate them with tumor progression or treatment response, and explore therapeutic strategies to restore PDCD5 activity. Additionally, PDCD5 antibodies have shown promise in identifying apoptotic pathways modulated by chemotherapeutic agents or radiation therapy. Recent studies also investigate their potential in autoimmune diseases, where PDCD5 may influence immune cell apoptosis.

Commercial PDCD5 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry. Ongoing research aims to refine antibody specificity and explore clinical applications, such as prognostic biomarkers or therapeutic targets to enhance chemotherapy sensitivity or gene therapy approaches.